Caribou Biosciences said its off-the-shelf CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...

DNA polymerases lie at the heart of diagnostic techniques like polymerase chain reaction (PCR), enabling early detection of ...

Virginia Tech scientists found that age-related memory loss stems from molecular changes in the brain. Memory decline might not be just a natural part of aging. Researchers at Virginia Tech have ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

Researchers have discovered that bacteriophages can effectively treat antibiotic-resistant Staphylococcus aureus infections, showing significant clinical improvements compared to traditional ...

New research led by the University of Minnesota Medical School demonstrates that molecules acting as "molecular bumpers" and "molecular glues" can rewire G protein-coupled receptor (GPCR) signaling, ...

In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...

Imagine a surgeon in the middle of a complex operation, able to get instant biochemical feedback not from a lab down the hall ...

The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...